Neuracle Genetics, a clinical stage biotechnology company, is committed to improving patients' lives by harnessing the curative potential of gene therapy. We are developing innovative AAV gene therapy product candidates to treat retinal and neurological diseases with significant unmet needs. Leveraging our proprietary technologies, our product candidates are designed and optimized for safety and efficacy, with the goal of providing broader access to patients. Our lead product candidate, NG101, is designed to be the best-in-class AAV gene therapy for treating patients with wet age-related macular degeneration (wAMD). Our proprietary technologies enable the use of larger transgenes without compromising expression efficiency. Furthermore, our approach allows lower clinical doses than those of our competitors, potentially offering a superior safety profile while maintaining comparable efficacy. NG101 is currently in a Phase 1/2a clinical trial and is actively enrolling patients.